Kymab Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Kymab's estimated annual revenue is currently $38M per year.(?)
  • Kymab's estimated revenue per employee is $155,000

Employee Data

  • Kymab has 245 Employees.(?)
  • Kymab grew their employee count by 13% last year.
  • Kymab currently has 1 job openings.

Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity, haematology, infectious disease and other areas.